Etripamil + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Paroxysmal Supraventricular Tachycardia (PSVT)
Conditions
Paroxysmal Supraventricular Tachycardia (PSVT)
Trial Timeline
Mar 27, 2015 → Dec 1, 2016
NCT ID
NCT02296190About Etripamil + Placebo
Etripamil + Placebo is a phase 2 stage product being developed by Medpace for Paroxysmal Supraventricular Tachycardia (PSVT). The current trial status is completed. This product is registered under clinical trial identifier NCT02296190. Target conditions include Paroxysmal Supraventricular Tachycardia (PSVT).
What happened to similar drugs?
0 of 20 similar drugs in Paroxysmal Supraventricular Tachycardia (PSVT) were approved
Approved (0) Terminated (4) Active (16)
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02296190 | Phase 2 | Completed |
Competing Products
20 competing products in Paroxysmal Supraventricular Tachycardia (PSVT)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crovalimab + Eculizumab | Chugai Pharmaceutical | Phase 3 | 44 |
| Crovalimab + Placebo | Chugai Pharmaceutical | Phase 1/2 | 36 |
| Crovalimab + Eculizumab | Chugai Pharmaceutical | Phase 3 | 44 |
| Ravulizumab | AstraZeneca | Pre-clinical | 30 |
| Eculizumab | AstraZeneca | Phase 3 | 40 |
| Danicopan | AstraZeneca | Phase 3 | 47 |
| LNP023 | Novartis | Pre-clinical | 33 |
| Iptacopan (LNP023) | Novartis | Phase 3 | 40 |
| iptacopan | Novartis | Phase 2 | 35 |
| LNP023 | Novartis | Phase 2 | 35 |
| Iptacopan | Novartis | Pre-clinical | 30 |
| Iptacopan | Novartis | Phase 3 | 40 |
| LNP023 + Eculizumab + Ravulizumab | Novartis | Phase 3 | 40 |
| LNP023 | Novartis | Phase 3 | 47 |
| LFG316 + LNP023 | Novartis | Phase 2 | 35 |
| Iptacopan | Novartis | Phase 3 | 44 |
| Crovalimab | Roche | Phase 3 | 44 |
| ABP 959 + Eculizumab | Amgen | Phase 3 | 40 |
| Pegcetacoplan | Swedish Orphan Biovitrum | Pre-clinical | 33 |
| BMS-919373 + Placebo (Matching with BMS-919373) | Bristol Myers Squibb | Phase 2 | 27 |